Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,226 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial.
Ohmachi K, Tobinai K, Kinoshita T, Ishikawa T, Hatake K, Ichikawa S, Ohmine K, Kamitsuji Y, Choi I, Chou T, Tsukasaki K, Kumagai K, Taniwaki M, Uchida T, Kikukawa Y, Kubo K, Mihara K, Tsukamoto N, Izutsu K, Yoshida I, Ishida F, Usui N, Iida S, Murayama T, Ueda E, Kuriki H, Ando K. Ohmachi K, et al. Among authors: kubo k. Int J Hematol. 2018 Nov;108(5):499-509. doi: 10.1007/s12185-018-2497-0. Epub 2018 Jul 19. Int J Hematol. 2018. PMID: 30027429 Clinical Trial.
Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leukemia: a propensity score-based comparison from the Japan Society for Hematopoietic Stem Cell Transplantation registry.
Nagafuji K, Matsuo K, Teshima T, Mori S, Sakamaki H, Hidaka M, Ogawa H, Kodera Y, Kanda Y, Maruta A, Mori T, Yoshiba F, Ichinohe T, Kasai M, Takatsuka Y, Kubo K, Sao H, Atsuta Y, Suzuki R, Yoshida T, Tsuchida M, Harada M. Nagafuji K, et al. Among authors: kubo k. Int J Hematol. 2010 Jun;91(5):855-64. doi: 10.1007/s12185-010-0581-1. Epub 2010 May 14. Int J Hematol. 2010. PMID: 20464644
Randomized comparison of fixed-schedule versus response-oriented individualized induction therapy and use of ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia: the JALSG GML200 Study.
Wakita A, Ohtake S, Takada S, Yagasaki F, Komatsu H, Miyazaki Y, Kubo K, Kimura Y, Takeshita A, Adachi Y, Kiyoi H, Yamaguchi T, Yoshida M, Ohnishi K, Miyawaki S, Naoe T, Ueda R, Ohno R. Wakita A, et al. Among authors: kubo k. Int J Hematol. 2012 Jul;96(1):84-93. doi: 10.1007/s12185-012-1105-y. Epub 2012 May 26. Int J Hematol. 2012. PMID: 22639053 Clinical Trial.
A prospective analysis of clinical efficacy and safety in chronic myeloid leukemia-chronic phase patients with imatinib resistance or intolerance as evaluated using European LeukemiaNet 2013 criteria.
Murai K, Akagi T, Shimosegawa K, Sugawara T, Ishizawa K, Ito S, Murai K, Motegi M, Yokoyama H, Noji H, Tajima K, Kimura J, Chou T, Ogawa K, Harigae H, Kubo K, Oba K, Sakamoto J, Ishida Y. Murai K, et al. Among authors: kubo k. Eur J Haematol. 2015 Dec;95(6):558-65. doi: 10.1111/ejh.12536. Epub 2015 Mar 25. Eur J Haematol. 2015. PMID: 25703064 Clinical Trial.
A single high-resolution HLA mismatch has a similar adverse impact on the outcome of related hematopoietic stem cell transplantation as a single low-resolution HLA mismatch.
Fuji S, Kanda J, Kato S, Ikegame K, Morishima S, Miyamoto T, Hidaka M, Kubo K, Miyamura K, Tsudo M, Kobayashi H, Maesako Y, Eto T, Adachi S, Ichinohe T, Atsuta Y, Kanda Y; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Fuji S, et al. Among authors: kubo k. Am J Hematol. 2015 Jul;90(7):618-23. doi: 10.1002/ajh.24028. Am J Hematol. 2015. PMID: 25850370 Free article.
Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy.
Miyamura K, Miyamoto T, Tanimoto M, Yamamoto K, Kimura S, Kawaguchi T, Matsumura I, Hata T, Tsurumi H, Saito S, Hino M, Tadokoro S, Meguro K, Hyodo H, Yamamoto M, Kubo K, Tsukada J, Kondo M, Aoki M, Okada H, Yanada M, Ohyashiki K, Taniwaki M. Miyamura K, et al. Among authors: kubo k. Leuk Res. 2016 Dec;51:11-18. doi: 10.1016/j.leukres.2016.09.009. Epub 2016 Sep 5. Leuk Res. 2016. PMID: 27771544 Clinical Trial.
Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: an analysis of the JSHCT.
Murata M, Ikegame K, Morishita Y, Ogawa H, Kaida K, Nakamae H, Ikeda T, Nishida T, Inoue M, Eto T, Kubo K, Sakura T, Mori T, Uchida N, Ashida T, Matsuhashi Y, Miyazaki Y, Ichinohe T, Atsuta Y, Teshima T. Murata M, et al. Among authors: kubo k. Bone Marrow Transplant. 2017 Feb;52(2):252-257. doi: 10.1038/bmt.2016.247. Epub 2016 Nov 21. Bone Marrow Transplant. 2017. PMID: 27869808 Clinical Trial.
Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.
Murai K, Yamaguchi K, Ito S, Miyagishima T, Shindo M, Wakasa K, Inomata M, Nagashima T, Kondo T, Fujimoto N, Yamamoto S, Yonezumi M, Oyake T, Kowata S, Tsukushi Y, Mine T, Meguro K, Ikeda K, Watanabe R, Saito S, Sato S, Tajima K, Chou T, Kubo K, Oba K, Sakamoto J, Ishida Y; The Inter-Michinoku Dasatinib Study Group (IMIDAS). Murai K, et al. Among authors: kubo k. Eur J Haematol. 2018 Jan;100(1):27-35. doi: 10.1111/ejh.12969. Epub 2017 Oct 16. Eur J Haematol. 2018. PMID: 28895203 Clinical Trial.
2,226 results